Introduction
Regulatory T cells (Tregs) are specialized cells that control immune responses to pathogens and mediate immunological self-tolerance and homeostasis, as initially described by Sakaguchi et al. [1] . Multiple subsets of Treg populations have been described in the literature.
Naturally occurring Tregs are derived from the thymus [2, 3] . Thymus-derived Tregs (tTregs) are characterized by the expression of the transcription factor forkhead box P3 (FoxP3) and the interleukin-(IL-) 2 receptor -chain CD25 [4] . Most mouse tTregs also express glucocorticoid-induced tumour necrosis factor (TNF) receptor-related protein (GITR, TNFRSF18, CD357) and OX40 (TNFRSF14, CD134), both of which are members of the TNF receptor superfamily [5] . Although tTregs are considered to be naïve T cells, several human tTregs are derived from expanded populations of tTregs and are CD45R0
+ (e.g., memory T cells) [6] . tTregs are anergic in vitro (e.g., do not proliferate in response to TCR triggering) but appear to be a proliferating population in vivo. Identification of tTregs is more complex in humans than in mice, because FoxP3 is transiently expressed even by activated T cells. Further, FoxP3 immunostaining requires permeabilization of cells, preventing functional experiments. CD25 is a useful surrogate marker for Tregs. However, CD25 is highly expressed in activated T cells [7] [8] [9] [10] . The notion that tTregs exhibit higher expression levels of CD25 (CD25 high or CD25 bright ) is theoretically interesting but difficult to demonstrate in a standardized manner due to differences in the affinities of anti-CD25 antibodies (Abs) and flow cytometers. Furthermore, immunohistochemistry cannot discriminate between CD25
+ and CD25 bright cells. In addition, some Tregs are not CD25 + FoxP3 + [11] . Thus, additional markers have been examined with CD25. For example, tTregs have been identified based on CD4 + CD25 + CD127 − , [12] [13] [14] . Despite some evidence of plasticity, tTreg phenotype and function remain fairly stable [15] .
Peripherally derived Tregs (pTregs) form a more heterogeneous Treg subset and are derived from CD4 + effector T cells that become activated in response to microenvironmental signals [4] . Transforming growth factor-(TGF-) -producing Th3 cells and IL-10-producing Tr1 cells are examples of pTreg cells [2, 3, 16] . Several studies demonstrate that some pTreg subsets express low to undetectable levels of FoxP3 and/or CD25. For example, Bacchetta et al. showed that a peripheral CD4
+ T cell subset expressed FoxP3 and low levels of CD25 while having regulatory activity [17] . pTregs exhibit a high degree of plasticity and can expand in response to specific needs [18, 19] . Tregs are characterized by the expression of specific surface markers, some of which mediate immune suppression (Table 1) . Tregs produce factors, such as IL-10, IL-35, granzyme B, and TGF-, which also mediate immune suppression ( Table 1) . Suppression of effector T cells by tTregs occurs via cell-to-cell contact, whereas soluble factors mediate T cell suppression by pTregs. However, Tregs are highly complex cells. For example, CTLA-4, one of the molecules involved in cell-to-cell inhibition, is expressed by several pTregs. In addition, differences exist between the expression of Treg markers and mechanisms of regulation by mouse and human Tregs.
Expression levels of Treg markers differ among Treg subsets; many markers are not exclusively expressed in Tregs and are also markers of activated effector T cells. This complexity and the differences between human and mouse Tregs make it difficult to evaluate the roles of Tregs in human diseases and can yield contrasting results. The best molecular marker(s) to study active Tregs in autoimmune diseases and tumours remain unclear. In this review, we present data suggesting that GITR is a crucial marker of Tregs, especially functional Tregs, and can be used as a marker to purify and evaluate the number of active Tregs.
Expression of GITR in T Cells
Schaer et al., Clouthier and Watts, and our group suggested that GITR is expressed at intermediate levels in murine and human CD4
+ CD25 − naïve effector T cells [20] [21] [22] ; similar levels were found in CD8 + cells. However, reinterpretation of published data suggests that this is not completely true.
After murine GITR was cloned, our group used a goat IgG polyclonal anti-GITR antibody (AF524, R&D System) to evaluate GITR expression in murine T cells [23, 24] [10, 29] . Consistent with our results, a previous study reported a small subpopulation of CD4 + CD25 − GITR + cells among human peripheral blood lymphocytes [30] . Therefore, it is reasonable to conclude that GITR is expressed in such a small population of CD4 + effector T cells and that depletion of GITR + cells will not eliminate most CD4 + cells [27] [28] [29] . Indeed, Snell and colleagues have described distinct subsets of GITR low and GITR high cells [31] . Furthermore, real-time PCR experiments in sorted human subpopulations demonstrated that CD4 + CD25 − GITR − cells express GITR mRNA at levels that are 10-fold lower than those in CD4 + CD25 − GITR + cells [29] . Therefore, we propose that naïve CD4 + cells are GITR −/low cells even if some antibodies at some experimental conditions suggest that most CD4 + and CD8 + cells are GITR + .
CD4
+ T cells express high levels of GITR following activation. Studies suggest that GITR upregulation occurs rapidly following CD4
+ T cell activation and peaks after one day to three days [25, 32, 33] . However, GITR does not appear to be a marker of long-term activation [10, 34] . CD8 + T cells express high levels of GITR following activation too [20] . As demonstrated for the first time by Shimizu et 
GITR Participates in Costimulation of Effector T Cells
GITR is triggered by the ligand GITRL, which is mainly expressed in antigen-presenting cells (APCs) and endothelial cells [36] [37] [38] . GITR is also activated by a newly described GITR ligand called SECTM1A [39] . GITR costimulation activates T cell receptor-(TCR-) triggered CD4 + and CD8 + T cells, promoting proliferation ( Figure 1 ) [24, 25, [40] [41] [42] . GITR activation can be obtained by agonist anti-GITR Abs, soluble GITRL, or transfection of GITRL [24, 25, 40, 41, 43] . The costimulatory effect of GITR activation in T cells increases T cell expansion and cytokine production [24, 25, 40, 42] , exacerbates autoimmune/inflammatory diseases [44] [45] [46] , favours tumour rejection, performs viral and parasite clearance, and potentiates immune/inflammatory responses 
and CD8
+ T cells in GvHD [101] . One difference refers to the reciprocal interaction between GITR and CD28. During activation of CD4 + CD25 − cells, GITR upregulation depends on CD28 stimulation [41, 102] . On the contrary, CD8
+ cells cannot be stimulated by CD28 in the absence of GITR if suboptimal doses of anti-CD3 Ab are used; however, GITR can coactivate downstream functions in the absence of CD28 [103, 104] . Thus, in CD8 + cells, GITR is necessary for CD28 costimulatory activity. Expression of 4-1BB also depends on GITR expression in CD8
+ memory T cells [105] and GITR promotes survival of memory bone marrow CD8 + T cells [106] . A specific role for GITR activation in the stimulation of CD8 + T cells is well-defined during chronic viral infection [34, 104, 107] .
Interestingly, the number of CD8 + T cells is not affected when GITR is activated by a supraphysiological level of ligand in GITRL-transgenic mice [108, 109] ; thus, physiological GITR activation is sufficient to fully stimulate CD8 + T cells. Conversely, the number and phenotype of CD4 + T cells are dramatically altered in two different transgenic mice that constitutively express GITRL in B cells [108] or in most APCs (i.e., majority of B cells, DCs, NK cells, and a fraction of macrophages) [109] . The most impressive phenotypic change is CD4 + Treg expansion, as discussed in Section 5. However, CD4
+ effector T cell expansion and maturation are favoured as well. The number of CD4 + T cells with an effector memory-like (CD44 + CD62L − ) and central memory-like (CD44 + CD62L + ) phenotype increased by twofold in GITRL-B-cell transgenic mice compared to that of wild-type control mice. Robust activation of GITR in GITRL-APC-transgenic mice resulted in 10-fold activation of CD44 + CD62L − compared to that in wild-type control (at 10 weeks). Conversely, CD4
+ naïve T cells (CD44 − CD62L + ) decreased by two-to threefold in transgenic mice, suggesting that GITR-triggered naïve T cells tend to be more reactive against antigens and differentiate towards the memory phenotype.
GITR Is a Crucial Player in tTreg Differentiation
Thymic development of Tregs is a two-step process [110, 111] . First, TCR and CD28 signalling induce IL-2 and chromatin remodelling at the FoxP3 locus (Treg progenitors). The second signalling event is cytokine-dependent and leads to FoxP3 expression. Mahmud et al. recently demonstrated that this step involves three TNFRSF members (GITR, OX40, and TNFR2) ( Figure 1 ) [112] . In fact, Treg progenitors express high levels of GITR, OX40, and TNFR2. Combined neutralization of their ligands (GITRL, OX40L, and TNF) abrogates the development of Tregs and costimulation of GITR and OX40 results in a tenfold increased sensitivity to low doses of IL-2. Treg progenitors with TCRs of the highest affinity and the highest expression of GITR, OX40, and TNFR2 compete more effectively for the respective ligands and are more likely to differentiate into mature Tregs. As a consequence, GITR expression is high in mature tTregs.
GITR Is a Crucial Player in Treg Expansion
The role of GITR activation in the expansion of Tregs is supported by studies in mice ( Figure 1 ). The number of Tregs is lower in GITR-knockout mice [23, 41, 113] . GITR activation by an anti-GITR Ab costimulates Tregs and promotes loss of anergy in the absence of IL-2 [24, 25] . In the presence of IL-2 and anti-CD3 Ab, GITR activation by a GITRL-Fc fusion protein promotes proliferation of both effector and Treg cells; however, FoxP3 + cells exhibit a stronger response to ligation of GITR compared to that in FoxP3 − cells [114] . Indeed, treatment of mice with GITRL-Fc favors a preferential proliferation of FoxP3 + cells [114] . Other in vivo models confirm the in vitro findings. As expected, the number of FoxP3 + Tregs is higher in transgenic mice that overexpress GITRL in B cells or APCs, compared [74] . However, the effects of blocking GITR have not been tested.
Studies on GITRL −/− mice confirm the role of GITR activation in Treg expansion and/or generation [116] . In fact, the expansion or generation of Tregs is impaired in GITRL −/− mice after injection of the dendritic cell-inducing factor Flt3 ligand. Furthermore, the expansion or generation of OVAspecific Tregs is impaired after gene transfer of ovalbumin (using the adenoassociated virus AAV8-OVA). Considering that GITR activation is elicited even by the newly discovered GITR ligand, SECTM1A [39] , it is possible that these results would be even more relevant if GITR activation was abolished by loss of both GITR ligands (GITRL and SECTM1A).
In multiple sclerosis, treatment with IFN-increases the number of CD4 + CD25 + FoxP3 + Tregs following increased expression of GITRL in CD14 + monocytes [61] ; this may suggest that GITR activation favours Treg expansion in humans too. However, so far no study demonstrates the role of GITR in human Treg expansion.
Pharmacological Activation of GITR Transiently Inhibits Treg Activity
GITR stimulation enhances T cell proliferation/activation not only through costimulation of effector T cells but also by the inhibition of Tregs (Figure 1 ), as originally demonstrated by the Sakaguchi and Shevach groups using anti-GITR Abs [26, 35] . Other studies have demonstrated the same effect when GITR was activated by GITRL overexpressed in APCs [24, 40, 117, 118] . GITR stimulation abolishes the activity of other suppressor cells, such as retinal pigment epithelial cells [119] or CD4 + CD25 − T cells in aged mice [120] . The same effect is elicited when human Tregs are exposed to anti-GITR Abs [29, 121] .
Some studies indicate that increased proliferation of effector cells in response to GITR activation of effector T cells renders them more resistant to Treg suppression [122] . In this context, two studies suggest that GITR stimulation activates an unknown pathway in effector T cells distinct from that which is activated by CD28, blocking immunosuppression [41, 119] . However, other studies demonstrate that GITR stimulation activates transduction pathways in Treg cells that are responsible for Treg suppression. In particular, GITR signalling downregulates granzyme B [123] , degrades FoxP3 protein [124, 125] , phosphorylates c-Jun N-terminal kinase (JNK), and activates NF-B [126] . Furthermore, in vitro and in vivo experiments demonstrate that stimulation of GITR on Tregs underlies the increased activation of effector T cells during inflammatory responses or tumour rejection [24, 26, 45, [124] [125] [126] [127] .
The full activity of Tregs in GITRL-transgenic mice [108, 109] suggests that inhibition of Treg suppression is transient and may be due to overstimulation of GITR in a nonphysiological condition (pharmacological effects). Indeed, GITRdependent decrease in FoxP3 protein expression is not due to changes in the levels of FoxP3 mRNA, confirming that this is a transient effect.
Some studies demonstrate that the effect of anti-GITR Ab on the suppressive activity of Tregs depends on Treg depletion [128, 129] , which in turn depends on the binding of anti-GITR Ab with activating Fc receptors (Fc R) [129] . The increased susceptibility of Tregs compared to that of activated CD4
+ and CD8 + cells may be due to higher levels of GITR expression on Tregs. Studies suggest that the effect of anti-GITR Ab is tumour-specific and may depend on myeloid cells and natural killer cells present in tumours but not in draining lymph nodes [129] .
In conclusion, GITR activation has four distinct effects on Treg/effector cell interplay: (1) transient inhibition of Treg regulatory activity, (2) decreased sensitivity of effector T cells to Treg suppression, (3) killing of Tregs (at least within solid tumours), and (4) increased proliferation and expansion of the Treg compartment.
The most relevant of these four remains a matter of debate. The relative importance of each of these mechanisms depends on the context and the disease [21, 130] . Nonetheless, the balanced effects on Tregs may reduce the chances of adverse effects. Indeed, no overt autoimmunity was observed in adult animals treated with anti-GITR Abs [131, 132] .
GITR Is a Marker of Murine Tregs
The evidence supporting a crucial role for GITR in the maturation of tTregs and expansion of tTregs and pTregs includes the fact that tTregs and expanded pTregs constitutively express GITR. Indeed, GITR is expressed in many (if not all) subsets of Tregs.
Constitutive expression of GITR in murine tTregs was first described by McHugh et al. [35] and Shimizu et al. [26] and was confirmed by Zelenika et al. [133] . Cells with suppressive activity express high levels of GITR in FoxP3 transgenic mice [134] . Indeed, gene expression in the Gitr locus is regulated by NF-B and FoxP3 through an enhancer [135] . In FoxP3 transgenic mice, GITR expression is observed surprisingly in CD25
− cells, demonstrating that GITR represents [143] .
Functional studies confirm that GITR is a highly specific marker for identifying and isolating Tregs. Ono et al., for example, demonstrated that the transfer of GITR + -depleted T cell populations caused death in 90% of nude mice due to autoimmune diseases [28] . In contrast, injection of CD25 + -depleted cells did not cause death. The same study demonstrates that the transfer of GITR + -depleted T cells from NOD mice to NOD-SCID mice promotes the accelerated development of diabetes as compared to those transferred with CD25
+ -depleted T cells (one month after cell transfer versus more than two months). The former mice died or had to be sacrificed because of debilitation before or at seven weeks after transfer, whereas only 20% of the latter (transferred with CD25-depleted T cells) died at 12 weeks after transfer.
These studies demonstrate that GITR is expressed in many (if not all) Treg subsets and at much lower levels in effector T cells. Because it also allows CD25 − Tregs to be isolated, GITR appears to be a more useful marker than CD25. The big difference among the diseases observed in GITR + cell-depleted and CD25
+ cell-depleted mice suggests that either known CD25 − Tregs (e.g., Tr1 and double-negative cells) are crucial to immune homeostasis or the number of CD25
− GITR + cells is big and other CD25 − GITR + cell subsets with regulatory activities exist in mice.
GITR Is a Marker of Human Tregs
Soon after the discovery of GITR as a marker of murine Tregs [26, 35] , studies reported that GITR is coexpressed with CD25 and FoxP3 in human CD4
+ tTregs [121, 144, 145] Therefore, GITR is used as a human Treg marker in several studies. A PubMed search revealed 49 studies in the past three years that investigated the roles of Tregs in autoimmune/allergic diseases, tumours, and infections and reported GITR as a Treg marker (Table 2 ). More interestingly, GITR is found in memory/activated Tregs, as reported below. Several studies suggest that GITR is a marker of Tregs that are actively suppressing effector cells. This is supported by the association of GITR expression with other Treg activation markers (e.g., CTLA-4), the expression of GITR in antigenspecific Tregs and/or T cells that produce cytokines with suppressive activity (e.g., IL-10 and TGF-), the presence of GITR + cells in tissues with active Tregs (e.g., solid tumours), and functional studies on Tregs. Our purpose is to illustrate the relevance of GITR as a marker of human Tregs; thus, we focus mainly on studies performed in humans.
GITR Is Frequently Found in Memory and/or Active Tregs
Wang et al. characterized CD4 + and CD8 + T cell clones derived from the peripheral blood of patients infected with human herpes virus 6 (HHV-6) [90] . They found that HHV-6-specific T cell clones with suppressive activities expressed not only CD25 and FoxP3, as expected, but also GITR; furthermore, nonsuppressive HHV-6-specific CD4 + or CD8 The expression of GITR in Tregs isolated from severe allergic asthma patients was similar to that from mild to moderate asthma Not applicable The -163C/T (ss491228440) polymorphism in TNFRSF18 gene is not a susceptibility factor in uncomplicated malaria and parasitaemia in Congolese children [92] FoxP3 + The expression of CTLA-4, GITR, LAG-3, and IL-10 was significantly higher in Treg from filarial-infected patients compared with that in healthy controls [93] Journal of Immunology Research 11 described in human Tr1 clones (GITR + CD25 low ), in which FoxP3 downregulation results in the loss of GITR surface expression and Treg suppressive activity but does not alter CD25 expression [151] .
Treg dysregulation (decreased number or function) has been demonstrated in several autoimmune diseases. GITR expression appears to be lower in patients with type 1 diabetes (T1D) compared to that of controls, according to two studies. In the first study, the percentages of CD4 + CD25 high CD127 dim /− cells did not differ between children with T1D and controls, but mRNA levels of several Treg markers, including GITR, were lower in Tregs from children with T1D [152] . In the second study, the number of CD25 low cells, especially CD4 + CD25 low/− GITR + cells, was lower in T1D patients than in controls [60] . Even within the CD4 + CD25 high population, the number of GITR + cells was lower in T1D patients, indicating that GITR + Tregs (independent of FoxP3 or CD25 expression) are less abundant in T1D patients. These data suggest that GITR + Tregs are crucial for the control of T1D.
In several solid tumour types, a subset of tumour-infiltrating lymphocytes is formed by antigen-specific Tregs that inhibit other immune cells and prevent tumour rejection. Data from animal tumour models suggest that GITR + Tregs tend to infiltrate tumours. For example, Sacchetti et al. demonstrated that GITR expression in Tregs (CD4 + FoxP3 + cells) residing in a B16 melanoma is approximately 10-fold higher than that of Tregs in the spleens of the same animals [153] . In Colon26 tumours, Tregs found in tumour infiltrating lymphocytes (TILs) show approximately fourfold stronger GITR signals than those of the equivalent lymph node population [129] . The role of GITR as a TIL Treg marker has also been confirmed in humans. In head and neck squamous cell carcinoma (HNSCC), CD25 high cells were enriched and represented 3% of CD3 + CD4 + TILs compared to circulating CD3 + CD4 + T cells of the same patients, which comprised 1% of CD3 + CD4 + cells; circulating CD3 + CD4 + T cells of normal controls comprised 0.4% of CD3 + CD4 + cells [154] . Analysis of markers expressed on CD25 high cells among PBMCs and TILs from the same patients shows that some markers (e.g., FoxP3 and CTLA-4) are found in both Tregs at the same levels but others are not. In particular, a lower percentage of TIL Tregs express CCR7 (77% in TIL Tregs versus 49% in PBMC Tregs) and CD62L (28% versus 47%). A higher percentage of TIL Tregs express CD132 (20% versus 40%). TIL Tregs are fully active, as suggested by expression of FasL (57% versus 0%), intracellular IL-10 (71% versus 0%), and intracellular TGF (97% versus 0%) and as demonstrated by a much higher suppressive activity compared to that of PBMC Tregs from the same patients. Importantly, IL-10/TGF -producing TIL Tregs are best detected by GITR, which is expressed in 83% of TIL Tregs and about 5% of PBMC Tregs of patients. Thus, GITR is the main marker of active Tregs, at least in HNSCC tumour. Similar findings were found in glioblastoma tumours, where all tTregs (CD4 + FoxP3 + Helios + ) were GITR + [6] .
A study on patients with invasive breast cancer confirms the role of GITR, even if data were less impressive [78] . FoxP3 and CTLA-4 are expressed in about 20% of CD25 high cells among PBMCs and about 30% of the CD25 + cells infiltrating the tumours, resulting in an increase of about 1.5-fold in TILs. In contrast, GITR is expressed in about 5% of the CD25 high cells of PBMCs and about 30% of the CD25 + cells infiltrating the tumours, resulting an increase of about sixfold in TILs. In PBMCs of the patients, the mean frequency of CD25 high and CD25 low cells was more than twofold higher than in healthy controls and expression of GITR, CTLA-4, and CCR4 was significantly higher in both subsets [78] . Comparing T-lymphocyte phenotypes among the lymph nodes of three breast cancer patients, Krausz et al. demonstrated that CD4
+ CD25 low CD127 + GITR + cells are more abundant in tumour-positive lymph nodes than in tumour-negative lymph nodes of the same patient [77] . These findings suggest that tumour cells stimulate expansion of this Treg subset or that GITR + cells tend to accumulate within the tumour.
Studies on other tumours confirm the overall picture. Padovani et al. studied cervical tissue of healthy women in comparison with tissue from women infected with papillomavirus (HPV) or women with carcinoma [84] . Most (85%) of carcinoma samples showed high GITR expression, whereas only 41% of normal and low-grade cervical intraepithelial neoplasia samples showed high GITR expression. Moreover, most (78%) of the samples highly positive for HPV showed high GITR expression, whereas only 43% of the samples negative for HPV showed high GITR expression. No differences in CD25 staining were observed, suggesting that the presence of GITR + Tregs correlates with malignancy and HPV infection of the cervical stroma and possibly with Treg activity. von Rahden et al. demonstrated that GITR expression in TILs is associated with oesophageal adenocarcinomas in the absence of Barrett's mucosa [155] . In patients with hepatocellular carcinoma and liver metastases from colon cancer, the number of CD25 + FoxP3 + Tregs is significantly higher in tumours than that in tumour-free liver tissue. The MFI of GITR and ICOS are significantly higher in Tregs from tumours than in those from tumour-free liver tissue [81] .
In conclusion, GITR is associated with activation and increased suppressive activity of Tregs in both mice and humans.
Conclusions
GITR is a crucial player in differentiation of tTreg and expansion of Tregs, including both tTregs and pTregs. Indeed, some data suggest that GITR is associated with markers of memory cells. Approximately 70-80% of Tregs are memory T cells, and expanded Tregs are active, at least in some diseases (e.g., several solid tumour types); thus, it is not surprising that several studies support GITR as a marker of active Tregs. Moreover, some Treg subsets, including Tr1 cells, express low levels of classical Treg markers (e.g., FoxP3 and CD25) or do not express them at all despite exhibiting expression of GITR. For this reason, we believe that GITR + Tregs must be evaluated when considering increased or decreased numbers of Tregs in human diseases. Finally, the use of GITR as a marker to isolate Tregs should be considered as we have recently proposed [156] . a member of the TNF receptor superfamily, is costimulatory to mouse T lymphocyte subpopulations, " 
